GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT06577597
- Locations
- 🇬🇧
GSK Investigational Site, Middlesex, United Kingdom
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants
Phase 1
Recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 138
- Registration Number
- NCT06576271
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Study on the Safety of and Immune Response to Different Doses of an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
Phase 1
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Investigational RSV vaccine 6Biological: Investigational RSV vaccine 1Biological: Investigational RSV vaccine 2Biological: Investigational RSV vaccine 3Biological: Investigational RSV vaccine 4Biological: Investigational RSV vaccine 5Drug: Placebo
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 210
- Registration Number
- NCT06573281
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Phase 3
Recruiting
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Other: Placebo
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 440
- Registration Number
- NCT06572384
- Locations
- 🇬🇧
GSK Investigational Site, Leicester, United Kingdom
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT06567782
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
Phase 3
Recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSVPreF3 OA investigational vaccineDrug: Placebo
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2600
- Registration Number
- NCT06551181
- Locations
- 🇬🇧
GSK Investigational Site, Witney, United Kingdom
A Study of GSK5764227 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 281
- Registration Number
- NCT06551142
- Locations
- 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Phase 2
Recruiting
- Conditions
- Chronic Hepatitis B Virus InfectionHepatitis B
- Interventions
- Drug: Daplusiran/Tomligisiran Dose Level 1Drug: Daplusiran/Tomligisiran Dose Level 2Drug: Placebo
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 280
- Registration Number
- NCT06537414
- Locations
- 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Phase 3
Recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10356
- Registration Number
- NCT06534892
- Locations
- 🇬🇧
GSK Investigational Site, Witney, United Kingdom
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Recruiting
- Conditions
- Lupus Nephritis
- Interventions
- Other: None (Observational study)
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT06527872
- Locations
- 🇺🇸
GSK Investigational Site, Charlotte, North Carolina, United States